Lecanemab (also called Leqembi and made by Eisai) is for slowing progression in mild cognitive impairment or mild dementia due to Alzheimer’s disease (AD) in adults and has been licensed by The ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

There is a simple discount patient access scheme for risankizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact pricing@abbvie ...

Risankizumab (Skyrizi, AbbVie) is indicated 'for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were ...

Review and download supporting evidence. Includes the full guideline if available.

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. We have a new way of making ...

NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This comprised a comprehensive literature search and detailed review of the evidence from 5 sources, ...

This topic was considered by the chair and vice chair of NICE's highly specialised technologies evaluation committee. Committee members are asked to declare any interests in the technology being ...

Tools to help you put the guidance into practice.

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. We have a new way of making ...